1. Home
  2. YMAB vs MIO Comparison

YMAB vs MIO Comparison

Compare YMAB & MIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • MIO
  • Stock Information
  • Founded
  • YMAB 2015
  • MIO 2021
  • Country
  • YMAB United States
  • MIO United States
  • Employees
  • YMAB N/A
  • MIO N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • MIO Investment Managers
  • Sector
  • YMAB Health Care
  • MIO Finance
  • Exchange
  • YMAB Nasdaq
  • MIO Nasdaq
  • Market Cap
  • YMAB 192.4M
  • MIO 199.2M
  • IPO Year
  • YMAB 2018
  • MIO N/A
  • Fundamental
  • Price
  • YMAB $4.32
  • MIO $11.68
  • Analyst Decision
  • YMAB Buy
  • MIO
  • Analyst Count
  • YMAB 11
  • MIO 0
  • Target Price
  • YMAB $17.55
  • MIO N/A
  • AVG Volume (30 Days)
  • YMAB 182.8K
  • MIO 46.0K
  • Earning Date
  • YMAB 08-11-2025
  • MIO 01-01-0001
  • Dividend Yield
  • YMAB N/A
  • MIO 4.57%
  • EPS Growth
  • YMAB N/A
  • MIO N/A
  • EPS
  • YMAB N/A
  • MIO N/A
  • Revenue
  • YMAB $88,658,000.00
  • MIO N/A
  • Revenue This Year
  • YMAB N/A
  • MIO N/A
  • Revenue Next Year
  • YMAB $15.15
  • MIO N/A
  • P/E Ratio
  • YMAB N/A
  • MIO N/A
  • Revenue Growth
  • YMAB 4.92
  • MIO N/A
  • 52 Week Low
  • YMAB $3.55
  • MIO $9.18
  • 52 Week High
  • YMAB $16.11
  • MIO $11.36
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 43.02
  • MIO 35.49
  • Support Level
  • YMAB $4.23
  • MIO $11.78
  • Resistance Level
  • YMAB $4.62
  • MIO $11.85
  • Average True Range (ATR)
  • YMAB 0.24
  • MIO 0.07
  • MACD
  • YMAB -0.03
  • MIO -0.01
  • Stochastic Oscillator
  • YMAB 14.04
  • MIO 1.82

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About MIO Pioneer Municipal High Income Opportunities Fund Inc.

Pioneer Municipal High Income Opportunities Fund Inc. is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide holders of the Fund's common stock with a high level of current income exempt from regular federal income tax.

Share on Social Networks: